VELETRI Market Report 2026

The veletri market size has grown strongly in recent years. It will grow from $1.45 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to clinical efficacy of epoprostenol, rising diagnosis of pah, hospital reliance on iv prostacyclins, limited oral alternatives, improved pah survival rates.

The veletri market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing pah prevalence, growth in specialty pah centers, rising demand for stable formulations, expansion of infusion therapy adoption, increased awareness of pah. Major trends in the forecast period include growing adoption of non-refrigerated prostacyclin therapies, increased use of continuous infusion pah treatments, rising demand for advanced pah vasodilators, expansion of hospital-based pah management, increased focus on improving pah patient mobility.

The rising prevalence of venous diseases is expected to drive the growth of the VELETRI market in the coming years. Venous diseases are disorders in which the veins experience impaired blood flow, leading to swelling, pain, and potential complications such as varicose veins and deep vein thrombosis. The increase in venous disease cases is influenced by factors including an aging population, sedentary lifestyles, obesity, and enhanced diagnostic capabilities. Veletri is utilized to improve exercise capacity and alleviate symptoms in patients with venous diseases affecting the pulmonary vasculature. For example, in January 2025, the Centers for Disease Control and Prevention, a US-based government organization, reported that up to 900,000 individuals in the United States are affected by venous thromboembolism (VTE) annually, with an estimated 60,000 to 100,000 deaths attributed to VTE each year. Consequently, the growing prevalence of venous diseases is supporting the expansion of the VELETRI market.

The increasing healthcare expenditure is expected to drive the growth of the VELETRI market in the coming years. Healthcare expenditure refers to the total financial resources allocated to medical goods and services to maintain and enhance population health. Healthcare spending is rising as an aging population requires more frequent medical attention and long-term health services. Higher healthcare expenditure enables greater use of VELETRI by improving access to specialized PAH care, expanding reimbursement for high-cost therapies, and strengthening the clinical infrastructure necessary for continuous IV treatment. For example, in April 2025, according to the Office for National Statistics, a UK government department, total healthcare spending increased by 6.5% in nominal terms and by 2.4% in real terms between 2023 and 2024 after adjusting for inflation. Thus, the rising healthcare expenditure is driving the growth of the VELETRI market.

Major companies operating in the Veletri space are concentrating on broadening access through generic formulations, such as FDA-approved epoprostenol sodium injection, to offer more affordable treatment options for patients with pulmonary arterial hypertension. Generic Veletri refers to therapeutically equivalent versions of the branded epoprostenol product that comply with FDA standards for quality, safety, and efficacy, delivering the same clinical outcomes at a reduced cost. For example, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical firm, received FDA approval for its generic Veletri (epoprostenol sodium) injection. The product is available in multiple vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and provides the same prostacyclin mimetic activity as the branded version, supporting improved exercise tolerance and symptom management in PAH patients.

Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc.

North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veletri market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported prostacyclin APIs and infusion related components used in injectable and inhalation therapies. These impacts are most pronounced in North America and Europe, where production depends on specialized and tightly regulated supply chains. Rising tariff related expenses have influenced manufacturing costs, pricing strategies, and procurement planning for pulmonary vascular disease treatments. This has affected availability and affordability across hospital and specialty care settings. Positively, tariffs are supporting local pharmaceutical manufacturing initiatives, expanded domestic production capacity, and stronger regional supply chain resilience over the long term.

The veletri market research report is one of a series of new reports that provides veletri market statistics, including veletri industry global market size, regional shares, competitors with a veletri market share, detailed veletri market segments, market trends and opportunities, and any further data you may need to thrive in the veletri industry. This veletri market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

VELETRI (epoprostenol) is a prostacyclin vasodilator prescribed for pulmonary arterial hypertension (PAH). It works by relaxing blood vessels in the lungs, reducing blood pressure, and enhancing blood flow. In contrast to Flolan, VELETRI does not need to be refrigerated, offering greater convenience for continuous infusion. It is given intravenously to help improve exercise tolerance and alleviate symptoms in patients with PAH.

The main product forms of VELETRI are injectable and inhalation. Veletri injectable is a prostacyclin (epoprostenol) therapy used to treat pulmonary arterial hypertension (PAH), helping to improve exercise capacity and alleviate symptoms. Its applications include pulmonary arterial hypertension and other related conditions, and the products are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

The VELETRI market consists of sales of injections, biosimilars, infusion systems, and related equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.